In an attempt to boost shareholders' value,
Merck & Co. Inc.
) - the N.J. based major drug manufacturer - entered into an
The Goldman Sachs Group, Inc.
) to repurchase $5 billion of its shares. The deal comes under
the $15 billion share buyback program approved by the company's
board of directors earlier in May.
ENDO PHARMACEUT (ENDP): Free Stock Analysis
GOLDMAN SACHS (GS): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
According to the pact, Merck will initially repurchase about 99.5
million shares from Goldman at current market prices. The
remaining shares will be repurchased by Nov 25 based on its
volume-weighted average stock price. The company plans to
repurchase approximately $7.5 billion worth shares through the
next 12 months.
We believe that the aforementioned deal was an effort by the
pharmaceutical major to appease investors, given the falling
stock prices in the recent years. Further, a dismal outlook for
2013 was a headwind.
Of late, Merck has been struggling to enhance profit levels, as
its asthma medicine Singulair was under pressure from generic
competitors in the U.S., following its patent expiry in Aug 2012.
In first-quarter 2013, sales of Singulair were $337 million, down
75% from the year-ago period. Singulair also lost exclusivity in
the EU in Feb 2013 and is experiencing sharp sales reduction in
that zone too.
Singulair was Merck's flagship product, with annual sales of $4
billion in 2012, before generics with cheaper selling prices
flooded the U.S. market. These companies include Endo
Pharmaceuticals - a unit of
Endo Health Solutions
) - and
). Further, Merck has deferred the launch of new products.
Moreover, its migraine medicine Maxalt reported a drop in sales,
after patent expiry and its brain cancer medicine Temodar will
likely be under generic competition in the near term.
However, we remain optimistic about Merck's new product pipeline,
which is expected to offset decreasing revenues.
Merck currently carries a Zacks Rank #3 (Hold), whereas Goldman
carries a Zacks Rank #2 (Buy).